Monoclonal antibody showed no clear difference in mortality Mortality at latest compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with polyclonal antibody (low certainty).
Monoclonal antibody showed no clear difference in cancer Number of participants diagnosed with cancer compared with polyclonal antibody (low certainty).
Benznidazole may leads to higher clearance or reduction of antibody titres (N) (a) at 12 months (b)… compared with placebo (low certainty).
It is very uncertain whether nifurtimox changes clearance or reduction of antibody titres (N) compared with placebo (very low certainty).
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in infection Number of participants diagnosed with infection compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA induction showed no clear difference in cancer Number of participants diagnosed with cancer compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA may leads to higher acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in infection Number of participants diagnosed with infection compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with polyclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in cancer Number of participants diagnosed with cancer compared with polyclonal antibody induction (low certainty).